Evidence map›Paper›PMID 26963853›Full record

ArticleCell cycle (Georgetown, Tex.)2016

TGF-β activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth.

Savvas C Pavlides, Jon Lecanda, Julien Daubriac, Unnati M Pandya, Patricia Gama, Stephanie Blank, Khushbakhat Mittal, Pratibha Shukla, Leslie I Gold

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Multiple functions of p21 in cancer radiotherapy.Journal of cancer research and clinical oncology · 2021
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Savvas C Pavlidesa Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
Jon Lecandaa Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
Julien Daubriaca Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
Unnati M Pandyaa Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
Patricia Gamac Department of Cell and Developmental Biology , Institute of Biomedical Sciences, University of Sao Paolo , Brazil.
Stephanie Blanka Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
Khushbakhat Mittald Gynecologic Oncology, New York University School of Medicine Langone Medical Center , New York , NY , USA.
Pratibha Shuklaa Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
Leslie I Golda Department of Medicine , New York University School of Medicine Langone Medical Center , New York , NY , USA.
NYU Langone Health · USUniversidade de São Paulo · BR

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancerR01CA176502 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARDOZO, TIMOTHY J, GOLD, LESLIE INA · 2014 to 2018
$3.2M
NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA176502
6 · The paper itself

Abstract

We previously reported that aberrant TGF-β/Smad2/3 signaling in endometrial cancer (ECA) leads to continuous ubiquitylation of p27(kip1)(p27) by the E3 ligase SCF-Skp2/Cks1 causing its degradation, as a putative mechanism involved in the pathogenesis of this cancer. In contrast, normal intact TGF-β signaling prevents degradation of nuclear p27 by SCF-Skp2/Cks1 thereby accumulating p27 to block Cdk2 for growth arrest. Here we show that in ECA cell lines and normal primary endometrial epithelial cells, TGF-β increases Cdh1 and its binding to APC/C to form the E3 ligase complex that ubiquitylates Cks1 and Skp2 prompting their proteasomal degradation and thus, leaving p27 intact. Knocking-down Cdh1 in ECA cell lines increased Skp2/Cks1 E3 ligase activity, completely diminished nuclear and cytoplasmic p27, and obviated TGF-β-mediated inhibition of proliferation. Protein synthesis was not required for TGF-β-induced increase in nuclear p27 and decrease in Cks1 and Skp2. Moreover, half-lives of Cks1 and Skp2 were extended in the Cdh1-depleted cells. These results suggest that the levels of p27, Skp2 and Cks1 are strongly or solely regulated by proteasomal degradation. Finally, an inverse relationship of low p27 and high Cks1 in the nucleus was shown in patients in normal proliferative endometrium and grade I-III ECAs whereas differentiated secretory endometrium showed the reverse. These studies implicate Cdh1 as the master regulator of TGF-β-induced preservation of p27 tumor suppressor activity. Thus, Cdh1 is a potential therapeutic target for ECA and other human cancers showing an inverse relationship between Cks1/Skp2 and p27 and/or dysregulated TGF-β signaling.

Indexed as

Anaphase-Promoting Complex-CyclosomeCDC2-CDC28 KinasesCdh1 ProteinsCell Cycle CheckpointsCell Line, TumorCell NucleusCell ProliferationCyclin-Dependent Kinase Inhibitor p27Endometrial NeoplasmsEndometriumEpithelial CellsFemaleHumansProteasome Endopeptidase ComplexS-Phase Kinase-Associated ProteinsTransforming Growth Factor betaAnaphase-Promoting Complex-CyclosomeCDC2-CDC28 KinasesCdh1 ProteinsCKS1B protein, humanCyclin-Dependent Kinase Inhibitor p27Proteasome Endopeptidase ComplexS-Phase Kinase-Associated ProteinsTransforming Growth Factor betaAPC/CCdh1cell cycleE3 ligaseendometrial cancerendometriumgrowth-regulationp27kip1SCF-Skp2/Cks1TGF-βubiquitin proteasome system

Identifiers

PMID26963853
PMCPMC4889277
OpenAlexW2337970213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.